882045-60-5

Basic information

• Product Name: 2-(4-formylphenyl)-4,5-dihydrooxazole
• Synonyms: 2-(4-formylphenyl)-4,5-dihydrooxazole
• CAS NO: 882045-60-5
• Molecular Weight: 175.187
• Mol File: 882045-60-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(4-formylphenyl)-4,5-dihydrooxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-formylphenyl)-4,5-dihydrooxazole(882045-60-5)
• EPA Substance Registry System: 2-(4-formylphenyl)-4,5-dihydrooxazole(882045-60-5)

Safety Data

• Hazardous Substances Data: 882045-60-5(Hazardous Substances Data)

Upstream product

• 623-27-8 terephthalaldehyde, 
• 141-43-5 ethanolamine 
• 201230-82-2 carbon monoxide 
• 870-24-6 2-chloroethanamine hydrochloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 105-07-7 4-cyanobenzaldehyde 
• 41526-99-2 4-(4,5-dihydrooxazol-2-yl) benzonitrile 

Downstream Products

• 938461-53-1 1-[4-(4,5-dihydro-1,3-oxazol-2-yl)phenyl]-1-ethanol 

Relevant articles and documents

Ruthenium(II) 8-quinolinolates: Synthesis, characterization, crystal structure and catalysis in the synthesis of 2-oxazolines

Abstract New octahedral ruthenium(II) complexes (1-4) have been synthesized from the reaction of ruthenium(II) precursors [RuHCl(CO)(EPh3)3] (E = P or As) with the bidentate Schiff base ligands, 2-((2,6-dimethylphenylimino)methyl)quinolin-8-ol (L1) and 2-((2,6-diisopropylphenylimino)methyl)quinolin-8-ol (L2) in ethanol. These complexes have been characterized by elemental analyses, IR, UV-Vis, 1H, 13C and 31P NMR and ESI-Mass spectroscopy. The molecular structure of the complex [RuCl(CO)(PPh3)2(L2)] (2) was determined by single-crystal X-ray diffraction, which reveals a distorted octahedral geometry around ruthenium(II) ion. The catalytic activity of the new complexes was evaluated for the condensation of nitriles with ethanolamine under solvent free conditions. The processes were operative with aromatic and heteroaromatic nitriles and tolerated several substitutional groups. The studies on the effect of substitution over ligands, coligands, reaction time, temperature and catalyst loading were carried out in order to find the best catalyst in this series of complexes and favorable reaction conditions. A probable mechanism for the catalytic condensation of nitrile has also been proposed. The catalyst was recovered and recycled up to five times without significant loss of its activity.

DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION

To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1) : (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.